 The FDA has signed off investigational new drug application of Scopus BioPharma Incs NASDAQ: SCPS for CpG-STAT3siRNA, the companys distinctive immuno-oncology RNA therapy for the treatment of multiple cancers. A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at the City of Hope. 